INCA-6

Modify Date: 2024-01-04 18:10:52

INCA-6 Structure
INCA-6 structure
Common Name INCA-6
CAS Number 3519-82-2 Molecular Weight 284.30800
Density 1.38g/cm3 Boiling Point 464.2ºC at 760 mmHg
Molecular Formula C20H12O2 Melting Point N/A
MSDS N/A Flash Point 172.6ºC

 Use of INCA-6


INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the  calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling[1][2][3].

 Names

Name inca-6
Synonym More Synonyms

 INCA-6 Biological Activity

Description INCA-6 (Triptycene-1,4-quinone) is a cell-permeable NFAT inhibitor. INCA-6 specifically blocks targeting of NFAT(P) substrate to the  calcineurin (CN) phosphatase site and is an effective inhibitor of CN-NFAT signaling[1][2][3].
Related Catalog
In Vitro INCA-6 (5 μM; for 24-hour) prevents transient outward K+ current (Ito) downregulation in 3-Hz cells[1]. Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia[2].  INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of  thapsigargin (TG)[3]. INCA-6 (1.0 and 2.5 μM; 24 hours ) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation[4]. Cell Proliferation Assay[4] Cell Line: Human retinal microvascular endothelial cells Concentration: 0.5, 1.0, or 2.5 μM Incubation Time: 24 hours Result: Significantly inhibited VEGF-induced proliferation at 1.0 and 2.5 μM concentrations.
In Vivo INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR)[4]. Animal Model: Rats bearing OIR model[4] Dosage: 2.5, 5.0, or 25.0 μM Administration: Intravitreal injection on days 14(0) and 14(3) Result: Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.
References

[1]. Ling Xiao, et al. Mechanisms underlying rate-dependent remodeling of transient outward potassium current in canine ventricular myocytes. Circ Res. 2008 Sep 26;103(7):733-42.

[2]. Miho Shiratori,et al. P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways. J Neurochem. 2010 Aug;114(3):810-9.

[3]. Anand Mohan Prasad, et al. Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes. Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H173-80.

[4]. Colin A Bretz, et al. The role of the NFAT signaling pathway in retinal neovascularization. Invest Ophthalmol Vis Sci. 2013 Oct 25;54(10):7020-7.

 Chemical & Physical Properties

Density 1.38g/cm3
Boiling Point 464.2ºC at 760 mmHg
Molecular Formula C20H12O2
Molecular Weight 284.30800
Flash Point 172.6ºC
Exact Mass 284.08400
PSA 34.14000
LogP 3.28200
Index of Refraction 1.729

 Safety Information

Hazard Codes Xi

 Synthetic Route

~84%

INCA-6 Structure

INCA-6

CAS#:3519-82-2

Literature: Zhu, Xiao-Zhang; Chen, Chuan-Feng Journal of Organic Chemistry, 2005 , vol. 70, # 3 p. 917 - 924

~%

INCA-6 Structure

INCA-6

CAS#:3519-82-2

Literature: Bartlett; Ryan; Cohen Journal of the American Chemical Society, 1942 , vol. 64, p. 2649,2651

~%

INCA-6 Structure

INCA-6

CAS#:3519-82-2

Literature: Bartlett; Ryan; Cohen Journal of the American Chemical Society, 1942 , vol. 64, p. 2649,2651

~%

INCA-6 Structure

INCA-6

CAS#:3519-82-2

Literature: Clar Chemische Berichte, 1931 , vol. 64, p. 1676,1679

~%

INCA-6 Structure

INCA-6

CAS#:3519-82-2

Literature: Clar Chemische Berichte, 1931 , vol. 64, p. 1676,1679

 Synonyms

NFAT Activation Inhibitor III
triptycene quinone
Inhibitor of NFAT-Calcineurin Association-6
triptycene-1,4-quinone
triptycene-quinine
9,10-dihydro-9,10-o-benzenoanthracene-1,4-dione